We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

By LabMedica International staff writers
Posted on 09 May 2025

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance. More...

AATD is a genetic disorder where the body does not produce sufficient amounts of a protective protein, whereas COPD is typically the result of prolonged exposure to irritants such as cigarette smoke. AATD is the second most common genetic lung disease in the United States, following cystic fibrosis. Affecting roughly 1 in 3,000 to 1 in 5,000 individuals, it is estimated to impact about 100,000 Americans, although many cases remain undiagnosed, leading to delayed treatment and potentially worse outcomes. Researchers have now developed a groundbreaking molecular diagnostic test that can accurately diagnose AATD, addressing a long-standing challenge in the medical community.

The innovative 23-SNP alpha-1 antitrypsin (AAT) assay, developed by scientists at National Jewish Health (Denver, CO, USA), significantly enhances the speed and accuracy of diagnosing AATD by identifying multiple genetic mutations linked to the condition. In a study published in CHEST Pulmonary, the researchers validated the assay using 373 biological samples, demonstrating its capability to detect 20 pathogenic mutations in the SERPINA1 gene, which is responsible for producing AAT protein, as well as two normal variants and an additional variant that is still being studied.

This new assay expands the number of genotypes that can be detected, including rare alleles such as F, I, and some null alleles. The results showed 100% accuracy in identifying abnormal mutations in patients with AATD, greatly surpassing the traditional isoelectric focusing gel method and other molecular tests that only detect S and Z alleles. The researchers believe this test could serve as a foundation for newborn screening programs and at-home sample collection, offering a significant boost to early detection efforts.

“AATD is widely underdiagnosed, leading to delays in treatment that can worsen disease outcomes,” said Yongbao Wang, PhD, lead researcher and senior author on the paper. “Our test provides an accurate, comprehensive and rapid genotyping solution that can be implemented as a frontline diagnostic tool.”

“This is a significant step forward for both clinicians and patients,” added Sharon Kuss-Duerkop, PhD, senior scientist at National Jewish Health. “With quicker and more reliable results, we can diagnose AATD earlier and start appropriate treatments, potentially preventing severe lung and liver complications.”

Related Links:
National Jewish Health


New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Mini Vortex Mixer
Vornado
New
Droplet Digital PCR System
QX600 AutoDG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: The innovative doublet configuration and annular illumination overcome traditional metalens limitations (Photo courtesy of Tao Li and Jiacheng Sun/Nanjing University)

High-Resolution Metalens Doublet Microscope to Enhance Diagnostic Capabilities

Metalenses mark a groundbreaking leap in optical technology. Unlike traditional microscope objectives that rely on curved glass surfaces, metalenses utilize nanoscale structures to manipulate light at... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.